Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research

Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises to facilitate robust and clinically relevant screenings at unprecedented speeds, marking a significant advancement in cancer treatment development.

Ground-Breaking Organoid Panel Screening Accelerates Oncology Research

OrganoidXplore stands out with its large-scale organoid panel screening capability, driven by Crown Bioscience’s unique assay-ready (AR) organoid technology. This innovative approach demonstrates highly robust performance and promises to reduce research project timelines by a substantial two-thirds compared to traditional methods, as evidenced by studies presented at prominent international conferences.

Assay-Ready Organoids Set New Benchmarks in Preclinical Studies

The advanced assay-ready organoids have been proven to match freshly prepared organoids in accuracy across various assays, offering reliable and reproducible drug response comparisons. This breakthrough technology significantly expedites the research process, with results available within just six weeks — a threefold increase in efficiency over standard practices.

Tailored Organoid Panels Address Diverse Research Needs

Researchers are empowered with the choice between a Full Panel and a specialized KRAS Panel, depending on their specific objectives. The comprehensive Full Panel includes 50 models across seven cancer indications, with a corresponding selection of companion Patient-Derived Xenografts (PDX). The KRAS Panel zeroes in on mutations relevant to four cancer indications, with 25 diverse models available for a more focused approach.

Advanced Characterization Techniques Enhance Drug Discovery

Crown Bioscience complements OrganoidXplore with exhaustive next-generation sequencing (NGS) characterization, including whole exome and RNA sequencing. This enables faster biomarker identification, precise mechanism of action studies, and improves patient stratification, thus streamlining the drug discovery journey.

An Unparalleled Platform for Pioneering Oncology Research

Dr. Leo Price, Senior Vice President at Crown Bioscience, highlighted the unparalleled precision, speed, and reproducibility of OrganoidXplore, attributing these qualities to cutting-edge cryopreservation and assay automation technologies. This platform not only meets the rigorous demands of groundbreaking research but also underscores Crown Bioscience’s dedication to innovating oncology research and expediting the path to discovering new cancer therapies.